Kiernan Thomas DeAngelis - Aug 26, 2021 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Role: Chief Medical Officer
Signature: /s/ Kiernan Thomas DeAngelis by Dale A. Sander as Attorney-in-Fact
Stock symbol: HUMA
Transactions as of: Aug 26, 2021
Transactions value $: $0
Form type: 4
Date filed: 8/27/2021, 04:10 PM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HUMA	Stock Options (right to buy)	Award		+99.6K			99.6K	Aug 26, 2021	Common Stock	99.6K	$8.49	Direct	F1, F2
transaction	HUMA	Stock Options (right to buy)	Award		+1.58K			1.58K	Aug 26, 2021	Common Stock	1.58K	$10.28	Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The first 1/3 of the grant, for 33,192 shares, is vested and exercisable. The next 1/3 of the grant will vest on April 20, 2022 and the final 1/3 will vest on April 20, 2023.
F2	On August 26, 2021, Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc.
F3	Options to purchase 2,625 shares of Common Stock granted on 12/14/2020, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Accordingly, columns 5, 7, and 9 of Table II report the number of securities equal to three-fifths of the 12/14/2020 option grant.